Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jesus Tejero Bravo
University of Pittsburgh at Pittsburgh, Department: Public Health & Prev Medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Globin Solutions, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Tejero Bravo's conflict arises due to his interest as an inventor of the intellectual property being evaluated in animal research, which the University licensed to Globin Solutions, Inc. Dr. Tejero Bravo holds an ownership interest in Globin Solutions and serves as the company's Chief Scientific Officer and as a member of the company's Board of Directors.
Countermeasure Therapeutics for Acute Lung Injury
Acute lung injury can result from irritant chemical exposure released from terrorists' attacks including the intentional detonation of chemical plants, railroad car derailments, or chemical truck hijacking. Often fatal, an initial diagnosis of acute lung injury can be difficult because the onset of signs and symptoms can be delayed hours or days after exposure. Lethal acrolein exposures have resulted following accidental release during transportation and use. Terrorists? attacks often produce massive fires that also can result in acrolein exposure, as well as, carbon monoxide exposure. This proposal seeks to advance the development of therapeutics that can be used to treat victims of acrolein, carbon monoxide, and acrolein plus carbon monoxide exposure and thereby reduce mortality.
Filed on November 20, 2017.
Tell us what you know about Jesus Tejero Bravo's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Jesus Tejero Bravo filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jesus Tejero Bravo | University of Pittsburgh at Pittsburgh | Conflict of Interest | Globin Solutions, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.